Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002159 · ClinicalTrials.gov registry record · Phase 3
A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis
A Phase 3 study, sponsored by Janssen.
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
NCT00002159 is a Phase 3 study that has completed, run by Janssen. The registered enrollment target is 60 participants.
The verdict
NCT00002159, a Phase 3 study, has completed, sponsored by Janssen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
Study Summary
To assess the safety of intravenous itraconazole compared to amphotericin B in HIV positive or negative persons with blastomycosis or histoplasmosis.
Interventions
- DRUG Itraconazole
- DRUG Amphotericin B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002159
The ClinicalTrials.gov registry entry for NCT00002159 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Itraconazole is the first listed.
NCT00002159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002159 about?
NCT00002159 is a clinical study titled "A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis". To assess the safety of intravenous itraconazole compared to amphotericin B in HIV positive or negative persons with blastomycosis or histoplasmosis.
What is the current status of trial NCT00002159?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants.
What interventions are being tested in trial NCT00002159?
The interventions under investigation include: Itraconazole (DRUG), Amphotericin B (DRUG).
Who is sponsoring clinical trial NCT00002159?
This trial is sponsored by Janssen, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.